You just read:

Bexion Pharmaceuticals Doses First Patient in Phase I Trial of BXQ-350 For Patients with Advanced Solid Tumors at the University of Cincinnati Cancer Institute

News provided by

Bexion Pharmaceuticals

Sep 20, 2016, 12:17 ET